HESG yields 2000000.00% · ABBV yields 3.06%● Live data
📍 HESG pulled ahead of the other in Year 1
Combined, HESG + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of HESG + ABBV for your $10,000?
Health Sciences Group Inc., through its subsidiaries, provides various products used in nutritional supplements and functional foods and beverages in the United States. It primarily offers Shugr, a zero-calorie sugar substitute that tastes and bakes like cane sugar; and Sequesterol Advance Cardio Formula, a proprietary blend of clinically studied ingredients for the maintenance of cardiovascular health and a free-flowing circulatory system. The company also offers Aplevia, an antioxidant derived from apple peels; and Edible Sponges, an open-cell hydrocolloid product. It sells its products primarily through mass market retailers, such as mass merchandisers, drug stores, supermarkets, and discount stores, as well as through healthcare professionals and practitioners, and other media. Health Sciences Group was founded in 1996 as Centurion Properties Development Corporation and changed its name to iGoHealthy.com in 2000. It changed its name to Health Sciences Group, Inc. in 2001. The company is based in Newport Beach, California.
Full HESG Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.